- About
- IgAN
- Events
- Resource Center
- Simulators
What interests you?+Help Us Enhance Your NephU ExperienceHelp Us Enhance Your NephU Experience
User experience form
Archives
Utilization Of The International IgA Nephropathy Prediction Tool
Thank you for attending, we hope you enjoyed this webinar.
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Utilization Of The International IgA Nephropathy Prediction Tool
Background
IgA Nephropathy is the most common glomerulonephritis and a leading cause of End Stage Kidney Disease (ESKD). While historically IgAN has been described as a slow progressive disease1, more recent literature demonstrates disease progression is extremely heterogeneous with a 10-year risk of reaching ESKD varying between 5-50%2.
Did You Know?
A significant proportion of patients with IgA nephropathy qualify for immunosuppression therapy, despite having nonprogressive disease, while many patients experience kidney function decline who do not qualify for treatment2. Accurate assessment of a patient’s risk of progression is essential for shared decision making around therapeutic options.
Why Attend This Webinar?
To learn about the clinical, laboratory and histological risk predictors that make up the International IgAN Prediction Tool and gain an understanding of its clinical utility and future potential.
What You Will Learn
- Key risk predictors for disease progression in IgAN
- How to implement the International IgAN Prediction Tool in clinical practice
- Strengths and weaknesses of the tool
- Donadio JV et al. NEJM. 2002;347(10):738-748.
- Barbour SJ et al. JAMA Intern Med. 2019;179:942-952.
Kelly Reed, PhD
Nephrology Senior Medical Science LiaisonOtsuka Pharmaceutical Development & Commercialization, Inc.*
Kelly Reed, PhD, joined Otsuka in 2012 and is currently a Senior Medical Science Liaison on our Nephrology East Team. Dr Reed has collaborated with several national professional organizations and healthcare systems providing educational presentations on hyponatremia and Autosomal Dominant Polycystic Kidney Disease (ADPKD). She has been a leader in resource development for the MSL team, co-led the nephrology MSL new hire training program during expansion and served as a mentor to several MSL new hires. Dr Reed earned her doctorate from Virginia Commonwealth University in Richmond, Virginia and completed her clinical internship at the Mailman Center for Child Development in Miami, Florida, followed by a two year fellowship at Cincinnati Children’s Hospital Medical Center.
Sachin Hajarnis, PhD
Nephrology Medical Science DirectorOtsuka Pharmaceutical Development & Commercialization, Inc.*
Sachin Hajarnis, PhD is a Senior Medical Science Liaison at Otsuka Pharmaceuticals. Dr Hajarnis has a Bachelors and Masters in Life Sciences from University of Mumbai, India. He obtained a PhD in Biochemistry and Molecular Biology from Colorado State University. Dr Hajarnis joined the University of Texas Southwestern Medical school in Dallas, as a post-doctoral fellow in the department of Nephrology where he performed basic research on various aspects of Polycystic Kidney Disease (PKD). He continued his studies on the role of micro-RNAs in PKD as a Research Scientist for several years before joining his current position at Otsuka.
Ankur Shah is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc.
Kelly Reed is an employee of Otsuka Pharmaceutical Development & Commercialization
Sachin Hajarnis is an employee of Otsuka Pharmaceutical Development & Commercialization
Disclaimer: The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional.
May 2024 US.CORP.X.24.00124Registration
NephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the kidney health community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.©2025 Otsuka Pharmaceutical Development & Commercialization, Inc. All rights reserved. - IgAN
